GW Pharma's (GWPH) Price Target Raised to $152 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
Tweet
Share
E-mailGet Alerts GWPH Hot Sheet
Price: $218.96 --0%
Rating Summary:
13 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 26 | Down: 19 | New: 65
Rating Summary:
13 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 26 | Down: 19 | New: 65
Join SI Premium – FREE
Morgan Stanley maintained an Overweight rating on GW Pharma (NASDAQ: GWPH) and raised its price target to $152.00 (from $149.00).
For an analyst ratings summary and ratings history on GW Pharma click here. For more ratings news on GW Pharma click here.
Shares of GW Pharma closed at $88.49 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morpheus Research releases short report targeting Fervo Energy
- Pepco Group Nv (WA:PCO) PT Raised to PLN50.50 at UBS
- Lennar Corp. (LEN) Mentioned Cautiously at Hunterbook
Create E-mail Alert Related Categories
Analyst PT Change, Momentum Movers, Short SalesRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
